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5Foreword
On 16 June 1997, concerned that differences in legislation on new synthet-
ic drugs between the European Union Member States would lead to legal
vacuums and problems of cooperation and control, the Council of the
European Union adopted a joint action regarding the information exchange,
risk assessment and control of new synthetic drugs (1).
The joint action establishes an early-warning system which detects and
exchanges information on new synthetic drugs as soon as they arrive on the
European market. Subsequently, it provides a mechanism for assessing the
risks of these drugs and finally furnishes a decision-making process through
which these products may be placed under control in the EU Member States.
It is to my great satisfaction that the Scientific Committee of the European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has been
assigned a key role in the information exchange and risk-assessment stages
of this process under Articles 3 and 4 of the joint action. This, in turn, has
enhanced the Centre's cooperation with national scientific experts as well as
its relations with bodies such as the European Commission, Europol and the
European Agency for the Evaluation of Medicinal Products (EMEA).
The present Guidelines for the risk assessment of new synthetic drugs are the
end-product of work undertaken in 1998 by a steering group set up by the
EMCDDA's Scientific Committee in 1997 to define the optimal means of
assessing the health and social risks of new synthetic drugs. The Guidelines
were adopted at an enlarged and multidisciplinary Scientific Committee
meeting in Lisbon on 9 and 10 November 1998 (2) and will form the basis of
(1) OJ L 167, 25.6.1997. A joint action is a decision adopted unanimously by the EU Member
States within the framework of the third pillar of the Treaty on European Union (cooperation
in the fields of justice and home affairs). Synthetic drugs are psychoactive substances pro-
duced in laboratories and not derived from natural products. They include MDMA (ecstasy),
other amphetamines, LSD, etc. A Report on the risk assessment of MBDB in the framework
of the joint action on new synthetic drugs has been published as a companion volume to the
present publication (EMCDDA, Lisbon, 1999). 
(2) Attended by: the Scientific Committee members; independent experts nominated by the EU
Member States and the European Commission; and representatives of the European
Commission, the European Agency for the Evaluation of Medicinal Products and Europol. 
6all future risk-assessment procedures undertaken by the Centre within the
framework of the joint action.
Synthetic drugs differ from natural substances (cannabis, cocaine, heroin) in
that they are produced in clandestine laboratories in industrial countries.
Particularly worrying for authorities is the fact that the possible chemical
variations within each of these substances are extensive, with small chem-
ical changes generating new drugs with widely different pharmacological
properties.
The joint action underlines the 'dangers inherent in the development of syn-
thetic drugs' and calls for rapid action by the European Union Member
States. It is my sincere hope that these guidelines will play a significant role
in helping to minimise the harms related to these new substances.
Georges Estievenart
Director, EMCDDA
7Introduction
The task of performing risk-assessment studies under the terms of the joint
action on new synthetic drugs was assigned to an 'extended' EMCDDA
Scientific Committee in 1997. This task entailed assessing the possible risks
— including the health and social risks — caused by the use of, and traffic
in, new synthetic drugs, as well as the possible consequences of prohibition. 
The extended Scientific Committee noted that the risk assessment of chem-
icals in the European Union was a routine procedure regarding medicines,
pesticides, food additives and cosmetics. What was unique about the joint
action, however, was the very fact that it went beyond mere risk assessment
to consider the social repercussions of a particular drug and the potential
consequences of banning it. The first task faced by the Committee, therefore,
was to draft a set of principles or guidelines not only incorporating best
health risk-assessment practice but also suggestions corresponding to these
additional issues.
The Scientific Committee set up a five-person steering group to draft these
guidelines. The group consisted of the then Chairman Carlo Perucci (Italy),
Wolfgang Werdenich (Austria), Salme Ahlström (Finland), Ed Leuw
(Netherlands) and myself. The steering group held a brainstorming session in
April 1998 where an outline text was produced. This was later refined by
Richard Hartnoll (EMCDDA) and Ed Leuw, incorporating comments from the
rest of the Committee. The twin problems of lack of laboratory and socio-
logical data for new drugs and the varying quality of existing data were
extensively debated and pragmatic solutions were proposed.
As the document took shape, the steering group took the opportunity to dis-
cuss its contents with national experts on risk assessment. The document was
then submitted to the European Commission, Europol, the EMEA and the
World Health Organisation for consideration.
At a special meeting of the EMCDDA Scientific Committee in September
1998, which included an expert risk-assessment workshop, the comments of
individual Committee members, along with those of the partner institutions,
were incorporated into a final draft which was approved by the Committee
in preparation for the formal risk-assessment meeting on 9 and 10 November
1998. This meeting, involving the Scientific Committee, scientific experts,
8Europol and the EMEA, introduced a series of amendments to the document
and finally adopted the 'Guidelines for the risk assessment of new synthetic
drugs' as the basis for future work.
What has pleased me most about the process leading up to this first pub-
lished edition of the Guidelines has been the considerable involvement of
the Scientific Committee members and other partners in the drafting of texts.
As a result of their commitment, the document has been greatly improved
with each revision. The Guidelines constitute an organic set of formulae
which will continue to be modified in the future in line with new experience
and additional knowledge. This is a novel approach and, to date, has
involved fruitful cooperation between the EMCDDA staff and Committee
members, representing European cooperation at its best.
Dr Desmond Corrigan
Chairperson, Scientific Committee of the EMCDDA
9In brief:
The joint action on new synthetic drugs
* The joint action establishes a common mechanism for: exchanging information
on new synthetic drugs (via an early-warning system); assessing the risks of these
drugs; and providing a decision-making process through which these products
may be placed under control in the EU Member States. The EMCDDA is
assigned a key role in the first two stages.
* The joint action covers psychoactive substances (end-products rather than pre-
cursors) with a limited therapeutic value and relates to synthetic drugs which are
not currently listed in the schedules to the UN Convention on Psychotropic
Substances (Vienna, 1971) and which pose a threat to public health (1).
* Under Article 3 (exchange of information), the joint action identifies new syn-
thetic drugs appearing on the market in the European Union and rapidly collects
information on these substances. This information is collected by: the Reitox net-
work (2), coordinated by the EMCDDA, comprising national focal points (NFPs)
in each Member State which provide useful information from health and social
sources; and the Europol national units (ENUs), coordinated by Europol, which
provide information from law enforcement sources. These two channels inter-
exchange and rapidly transmit the information they receive.
* Once received from the Member States, the data are exchanged between
Europol and the EMCDDA and communicated to their respective networks, to
the European Commission, and to the EMEA. In this first phase, the information
gathered includes: a chemical and physical description of the drug, including
the name under which it is generally known; details on the frequency, circum-
stances and/or quantities in which a new synthetic drug is encountered; and a
first indication of the possible risks involved. As far as possible, information is
also provided on chemical precursors, the mode and scope of established or
expected use of the drug as a psychotropic substance as well as other uses of the
drug.
* Once this information has been exchanged, any Member State or the European
Commission may request the EMCDDA, under Article 4 of the joint action (risk
assessment), to convoke a meeting of experts under the auspices of its Scientific
Committee to determine the risks associated with a particular substance and the
possible consequences of its prohibition. In addition to the Scientific Committee
members, the experts consulted include scientific specialists nominated by the
Member States and representatives of Europol, the EMEA and the European
Commission.
(1) AUN Convention covering hallucinogens, amphetamines, barbiturates, non-barbiturates,
sedatives and tranquillisers.
(2) Reitox — the European information network on drugs and drug addiction — is a network
coordinated by the EMCDDA and composed of national focal points in the 15 EU
Member States plus the focal point at the European Commission.
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* Under Article 5, (procedure for bringing specific new synthetic drugs under con-
trol) the joint action allows the Council, on the basis of an initiative to be pre-
sented within a month from the date on which the report of the results of the risk
assessment is delivered, to adopt anonymously a decision defining the new syn-
thetic drug(s) which is(are) to be placed under control.
* This joint action meets the need to provide the EU with a more flexible and rapid
mechanism for tackling synthetic drugs. However, it does not prevent any
Member State from maintaining or introducing on its territory any national con-
trol measure it deems appropriate once a new synthetic drug has been identified
by a Member State.
11
Chapter 1
Basic principles for risk assessment
In accepting its assignment to assess the risks of new synthetic drugs, the
EMCDDA's Scientific Committee adopted the following basic principles.
1. Consider a dual definition of 'risk'
The concept of 'risk' should be understood in its dual sense, which includes
both the element of probability that some harm may occur (usually defined
as 'risk') and the degree of seriousness of such a harm (usually defined as
'hazard'). If possible, both elements should be evaluated in the final phase
of the risk-assessment process. In addition, and where feasible, a risk-benefit
ratio should be assessed for each candidate drug.
2. Consider the risks of a drug, independently of
its legal status
The first phase of the scientific risk assessment of a particular drug should be
carried out independently of its legal status.
3. Consider a wide range of options for control
Consideration of appropriate measures and possible consequences of con-
trolling new synthetic drugs should cover a wide range of options and should
not necessarily imply prohibition and law enforcement.
4. Consider scientific evidence on a new 
synthetic drug in relation to better-known
drugs
Since scientific evidence on new synthetic drugs will, by definition, often be
limited, it will thus be necessary to evaluate the possible risks of these drugs
with reference to similar known drugs. Consistent with principle 2 above,
12
such comparisons need not be restricted to illegal drugs but may include
legal substances with similar chemical characteristics, pharmacological
actions or psychological and behavioural effects, or which offer relevant
insights into the social risks presented by the drug. Similarly, when assessing
the possible consequences of prohibition, taking note of principle 3, it may
be appropriate to examine relevant examples of control models involving
legal or illegal substances. Considerer weighting separately the issues of reli-
ability and relevance.
In the final evaluation, the issues of reliability of information (quality) as well
as the relevance of the specific risk issues involved (health and social risks
and consequences of prohibition) should be weighted separately. The final
policy consequences of risk assessment should be decided within the frame-
work of national or local drug policy priorities.
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Chapter 2
A conceptual framework for risk assessment
Risks related to any psychoactive drug, whether legal or illegal, medical or
recreational, can originate from several sources and assume many shapes
and forms. For both analytical and pragmatic purposes (social control
options), it is essential to clarify both the type and origin of drug-related risks
as they manifest themselves in society.
The following framework presents a conceptual structure within which el-
ements of drug-related risk may be located and evaluated in terms of rele-
vant control options. The framework is built on the distinction between the
sources from which drug hazards emanate (Box 1) and the type of hazardous
effects that may be caused by drug use (Box 2).
1. Sources of hazards 
Within the social reality of drug use, harmful effects may emanate from sev-
eral domains which may exist independently of each other. Cannabis will
serve as an example. Possible harmful consequences of use may be 'caused'
by the drug's pharmacological effects (properties of the substance), for
instance when acute intoxication impedes the ability to drive a car and
hence increases the chance of traffic accidents. Possible long-term effects on
memory functions may be another case in point.
Careful and moderate use of cannabis may not coincide with any apparent
undesirable psychological or somatic effect. However, harmful effects could
emanate from moral stigmatisation or criminalisation of use of cannabis
which, for instance, could result in the dismissal of cannabis users from
school (measures of social control). In other cases, the undesirable effects
might be contingent on the specific 'style' and context of drug use.
14
For clear examples, drugs other than cannabis will need to be considered.
Some of the well-known harmful effects of MDMA (ecstasy) are contingent
on the context of 'rave' parties: prolonged and intensive dancing in badly
ventilated, crowded areas which accentuate a pharmacological effect on
body temperature. A well-known case of 'style' as a source of drug hazard is
the relationship between intravenous drug use and HIV infection. The high
prevalence of HIV infection in populations of drug addicts has less to do
with the drugs themselves and more to do with lifestyles (modalities of drug
use).
There may also be interaction between the different sources of hazard them-
selves and this must also be taken into account. For example, whether or not
pharmacological tolerance of opioids leads to injection is influenced by fac-
tors such as cultural setting, economic factors, formal policies and informal
norms. Distinguishing domains from which the harmful effects of drugs orig-
inate has obvious consequences for the drug policy options to be taken after
the risk-assessment procedure.
2. Hazardous effects 
The harmful effects of drugs and the drugs market can be conceived as 
having an impact on the user, the social environment of drug use and on
society in general. In this case, it is inappropriate to assume that different
hazardous effects are independent of each other.
Harmful effects on the user (biological, psychological, behavioural) tend to
be directly linked to harmful effects on the social environment of drug use
(family, neighbourhood and community, society at large) making dividing
lines difficult to draw. Similarly, it is hard to make a clear distinction between
the different 'levels' of harms caused to the user or to the social environment.
Box 1
Sources of hazard
Sources of hazard emanating from:
* properties of the substance (pharmacology and toxicology)
* measures of social control (regulatory policies and informal norms)
* modalities of drug use (patterns, context of use)
* individual characteristics of users (age, gender, genetic, personality)
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Somatic effects will often have obvious consequences for psychological
functions which, in turn, are also relevant for social behaviour. The example
of alcohol illustrates this point: toxic effects on the central nervous system
may cause cognitive dysfunction which, in turn, may lead to irresponsible
social behaviour. Nevertheless, for analytical purposes and policy options, it
is still useful to distinguish between different categories of harm.
Three aggregate levels can be distinguished in the social environment: the
micro level (family); the meso level (neighbourhood and community); and
the macro level (society at large). Particularly on the meso and macro levels,
it is advisable to take note of the consequences of the drug distribution sys-
tem separately. Independent of the properties of the substance, the nature of
the illicit market may cause harmful effects, such as problems of public order
and security on the streets. On the macro level, the drug trade may be harm-
ful for the integrity of economic or law-enforcement institutions.
The risk assessment of new synthetic drugs should include a strategy for
deciding the different weights and priorities of both the sources and the
effects of drug hazards for the final evaluation.
Box 2
Hazardous effects of drugs
(a) On the user
* biological (toxicity, dependence)
* psychological (functional impairment, effects on personality)
* behavioural (neglect of social roles, violence, etc.)
(b) The social environment
* family — micro level (disruption, neglect, violence) 
* neighbourhood and community — meso level (public order and 
safety)
* society at large — macro level (economy, public health and judicial
systems)
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Chapter 3
Quality of information for risk assessment
As implied by the very nature of the assignment at hand (i.e. to assess the
risks of new synthetic drugs), it will often be impossible to base the risk
assessment on the evaluation of sound (reliable and valid) scientific knowl-
edge. Pharmacological and socio-scientific knowledge will accumulate in
time and will have to be assembled over a period of social experience with
the drug phenomenon. In the interim, risk assessment will have to be based
on a broad range of available evidence. The (scientific) quality of this evi-
dence should be appraised according to the two criteria outlined below.
1. Methodological characteristics of the available
evidence
From a methodological point of view, evidence for risk assessment may be
produced by more or less rigorous scientific procedures.
Detailed biomedical data, based on systematic pharmacological and toxico-
logical studies, will rarely be available for new synthetic drugs.
In the case of socio-scientific data, evidence from preliminary, impressionis-
tic accounts may be more available than evidence from methodologically
more rigorous and objective studies, such as surveys or panel studies.
2. Sources of available evidence
The risk-assessment procedure should include a strategy for using data from
sources of different quality. Evidence is likely to originate from sources with
a wide range of reliability: from peer-reviewed publications in prominent
scientific journals, through reports by youth workers or psycho-medical
institutions, to unsubstantiated newspaper or Internet reports. A possible
method of classifying this information is to use the type of ranking listed in
Box 3.
A differential strategy as regards the acceptance of information may be the
most sensible approach. In the first instance, the identification and collection
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of available data will involve accepting a wide range of information —
including information that may be useful for signalling phenomena of pos-
sible relevance — and then applying different weights based on a hierarchy
of data quality when screening the evidence to be considered in the final
evaluation process.
Box 3
Classification of information sources
Ia Indexed, peer-reviewed scientific publication, 'high' impact factor
Ib Indexed, peer-reviewed scientific publication, 'low' impact factor
II Official reports of governments or international agencies
IIIa Non-indexed, peer-reviewed scientific publications
IIIb Other reports or scientific publications
IV Other sources (media, individual reports, unofficial publications)
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Chapter 4
Headings for risk assessment
In any risk-assessment procedure, a number of headings are recommended
under which the information may be organised in a 'checklist' manner.
These headings, as outlined below, include: a description of a new synthet-
ic drug and its actions; health risks; social risks; options for control and the
possible consequences of prohibition; and weighting the criteria (1).
As outlined in Chapter 1, the probability (risk) and seriousness of the adverse
consequences of a substance (hazard) should be taken into account at the
beginning of the risk-assessment procedure. Under all headings, the specific
drug should be studied in terms of its similarities to, and differences from,
other relevant psychoactive substances, especially those for which estab-
lished scientific literature exists. As also stated in Chapter 1, other relevant
substances should be selected on the basis of their chemical and/or 
pharmacological resemblance to the drug concerned, or with regard to the
insights they offer concerning social risks. This selection should not neces-
sarily be restricted to illegal drugs.
In assessing the risks of a particular drug, five key variables likely to affect
the hazards and risks related to that drug should be taken into consideration
as outlined in Box 4.
Box 4
Key variables
* Dose and frequency of use
* Short-term and especially long-term effects
* Interactions with other substances (including alcohol and medicaments)
* Individual characteristics
* Characteristics of the social environment
(1) A protocol setting out headings for the risk-assessment process in more detail is appended to
this publication as a series of technical annexes.
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The information gathered in any risk-assessment process is likely to be based
on different types of evidence as outlined in Box 5.
Box 5
Types of evidence
* Laboratory evidence, either in vitro or in vivo (mainly animals)
* Evidence of effects on humans (physical, mental)
* Epidemiological evidence
* Social and criminological evidence
In evaluating the consistency between laboratory-based and population-
based evidence, special account must be taken of social context factors, and
of the selection of population groups and individual users as potential
sources of bias when inferring the social and health risks of a specific drug.
1. Description of a new synthetic drug and its
actions
The description of a new synthetic drug and its actions should include the
elements set out in Box 6.
Box 6
Descriptive elements
* Name of the drug, physical description, chemical composition, pharma-
cological effects in animal and human studies, known uses, and similar-
ity to other relevant substances
* Its actions on the central nervous system
* Its actions on other organs and systems
* Its psychological and behavioural effects on humans (cognition, mood,
personality, behaviour, motor function)
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2. Health risks
Possible health risks include both the risks to individual health, resulting
from the use of a new synthetic drug, and the public health risks, affecting
the broader community. There is not always a clear dividing line between
individual and public health risks, nor between public health risks and social
risks. Most of the health risks, especially the individual health risks, are 
likely to be the consequences of the use of the drug. However, some of the
public health consequences may also be linked to the nature of the produc-
tion and trafficking of the drug (e.g., the purity and quality of the drug on the
market).
Individual health risks
Assessment of the individual health risks of a new synthetic drug should
cover physical and psychological, short-term and long-term aspects and
should include the elements listed in Box 7. Dose, frequency, route of
administration and interactions with other drugs are important factors to
consider.
Box 7
Elements for assessing individual health risks
* Acute toxicity
* Chronic toxicity
* Dependence potential (physical and psychological)
* Psycho-social dysfunction
* Similarities and differences to other reference drugs
Public health risks
Assessment of the public health risks of a new synthetic drug should include
epidemiological and other evidence as listed in Box 8.  
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3. Social risks
Some public health risks (e.g., road traffic accidents) could also be listed
under the heading of social risks. Apart from such examples, social risks
include the following elements.
Box 8
Elements for assessing public health risks
* Availability and quality of the drug on the market (purity, adulterants, etc.)
* Availability of information, degree of knowledge and perceptions
amongst users concerning the drug and its effects
* Extent, frequency and patterns of use of the drug
* Characteristics and behaviours of users (including risk factors, vulnera-
bility, etc.)
* Nature and extent of health consequences (e.g., acute emergencies, 
poisonings, road traffic accidents)
* Long-term aspects
* Conditions under which the drug is obtained and used, including 
context-related effects and risks (e.g., continuous dancing in hot 
environments, other drugs used)
Box 9
Elements for assessing social risks
* Individual social risks
* Possible effects on family (neglect, violence, etc.)
* Possible effects related to the cultural context, for example marginalisa-
tion
* Possible attractiveness of a drug to specific populations within the 
general population
* Impact on the production, trafficking and distribution of other drugs,
including existing synthetic drugs as well as new synthetic drugs
* Drug-related crime linked to use of the drug
* Effects associated with production, trafficking and distribution of the
drug, including the involvement of organised crime
* Impact on social groups and local communities (public order and 
safety)
* Economic costs
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4. Options for control and the possible 
consequences of prohibition
As noted in the basic principles set out in Chapter 1, assessment of the pos-
sible consequences of prohibition has been set within the broader context of
assessment of the possible consequences of different control options, includ-
ing, but not restricted to, prohibition and law enforcement.
In assessing the possible consequences of prohibition, it is appropriate to
examine a range of control models (e.g., administrative or public health
regulatory frameworks for alcohol, tobacco, medicines or poisons). The
assessment should examine the consequences of different control options on
the factors listed in Box 10.
Box 10
Elements for examining the consequences of control options
* Production, trafficking and organised crime
* Distribution and availability
* Quality and price of the drug on the market
* Impact on the market in, and use of, other drugs (including the likeli-
hood of alternative new drugs emerging)
* Prevalence and patterns of use of the drug
* Health consequences
* Social consequences
* Other uses of the drug in pharmaceutical research, medicine, industry,
trade, etc.
* Existing legislation, law enforcement, judicial and other control systems
* Specific cost implications (e.g., the additional costs of product testing or
forensic analysis)
5. Weighting the criteria
When evaluating the available evidence and assessing the possible risks of a
particular drug, it will be necessary to decide how, and in what form, the
results should be presented. For example, it may be necessary to consider
whether (and, if so, how) to give different weights to the different possible
effects and consequences.
It is clear that these aspects need to be further refined. In order to estimate
the risks of a substance, more or less quantitative methods could be used or
developed. In order to weigh the evidence, data on a new synthetic drug
could be compared with data for existing legal or illegal substances. For this
purpose, a multidimensional reference system could be developed.
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Technical Annex A
Pharmacotoxicological evidence
A1. Chemical, pharmaceutical information
A1.1. Chemical description (including methods of synthesis, precursors,
impurities if known — type and level)
A1.2. Legitimate uses of the product
A1.3. Pharmaceutical form (i.e., powder, capsules, tablets, liquids,
injectables, cigarettes. Any distinctive markings, logos, etc., to be
noted)
A1.4. Route of administration and dosage (e.g., oral, inhalation, 
intravenous, etc.)      
A2. Toxicology and pharmacology in animals
A2.1. Pre-clinical safety data
A2.1.1. Single-dose toxicity
A2.1.2. Repeated-dose toxicity
A2.1.3. Reproduction function
A2.1.4. Embryo-foetal and perinatal toxicity
A2.1.5. Mutagenic and carcinogenic potential
A2.2. Pharmacodynamics
A2.2.1. In vitro tests (data from enzyme, receptor binding,
immunomodulatory and hormonal tests)
A2.2.2. In vivo tests
* effects on central nervous system
* effects on cardiovascular system
* effects on respiratory system
* effects on gastrointestinal system
* effects on liver, kidneys, genitourinary system
* behavioural studies
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A2.2.3. Pharmacokinetics in animals
* absorption
* distribution
* metabolism 
(including major metabolising enzymes and metabolites)
* excretion (including elimination half-life)
* pharmacokinetic interactions
A3. Human pharmacology
A3.1. Laboratory studies in volunteers
A3.1.1. Effects on cognition and behaviour
A3.1.2. Cardiovascular effects
A3.1.3. Respiratory effects
A3.1.4. Gastrointestinal effects
A3.1.5. Effects on liver, kidneys, genitourinary system
A3.1.6. Effects on immune system
A3.1.7. Interactions with other drugs and medicines
A3.1.8. Effects on ability to drive and use machinery
A3.1.9. Effects of overdose
A3.2. Pharmacokinetics in humans
A3.2.1. Absorption
A3.2.2. Distribution
A3.2.3. Metabolism (including major metabolising enzymes and
metabolites)
A3.2.4. Excretion (including elimination half-life)
A3.2.5. Pharmacokinetic interactions
A4. Clinical experience
A4.1. Studies on street users
A4.2. Dependence potential in humans
A4.2.1. Tolerance
A4.2.2. Abstinence symptoms
A4.2.3. Drug-seeking behaviour
A4.3. Clinical safety (see Annex D, Section D5).
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Technical Annex B
Psychological risk assessment
(cognition, mood and mental functioning)
B1. Acute effects
B1.1. Effects on cognitive functioning (neuropsychological assessment)
B1.2. Effects on intelligence (multifactorial intelligence tests)
B1.3. Effects on emotional status, behavioural patterns and personality
(psychological instruments, rating scales)
B1.4. Effects on psychopathological status — psychiatric comorbidity
(psychological and psychiatric assessment)
B2. Chronic effects
B2.1. Effects on cognitive functioning (neuropsychological assessment)
B2.2. Effects on intelligence (multifactorial intelligence tests)
B2.3. Effects on emotional status, behavioural patterns and personality
(psychological instruments, rating scales)
B2.4. Effects on psychopathological status — psychiatric comorbidity
(psychological and psychiatric assessment)
B3. Psychological effects of drug-using careers
B4. Psychological factors that increase the 
probability of harm (e.g., mood and anxiety
conditions leading to self-medication, 
sensation seeking)
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Technical Annex C 
Sociological/criminological evidence
C1. Social consequences for the user
C1.1. Primary relations and/or family problems
C1.2. Education and employment problems
C1.3. Marginalisation
C2. Consequences on the social behaviour of 
the user
C2.1. Drug-related disorderly conduct
C2.2. Drug-related acquisitive crime
C2.3. Drug-related violence
C2.4. Drug-related traffic offences
C3. Other social consequences
C3.1. Presence or absence of major value conflicts surrounding the use of
the drug
C3.2. Implications for social institutions (school, labour, recreational,
etc.) and community services
C4. Wholesale production and distribution
C4.1. Violence in connection with wholesale production and distribution
C4.2. Money-laundering aspects
C4.3. Involvement of (international) organised crime
30
C5. The retail market
C5.1. Non-commercial 'private' consumption market among users
C5.2. Semi-public subcultural consumption market (discos, etc.)
C5.3. Existence and characteristics of street markets
C5.4. Violence, public order and nuisance implications of the retail 
market
C5.5. Entrepreneurial criminal suppliers
C6. Social factors that increase the probability of
harm
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Technical Annex D
Public health risks: epidemiological evidence
D1. Availability and quality of product on the
market
D1.1. Availability at consumer level (extent/quantities)
D1.2. Sources (at consumer level)
D1.3. Trends in availability
D1.4. Average dose and degree of variability
D1.5. Purity levels and presence of adulterants
D1.6. Other active ingredients
D1.7. Typical prices and range
D2. Knowledge, perceptions and availability of
information
D2.1. Availability of scientific information on product
D2.2. Availability of information on effects of product
D2.3. Level of awareness of product amongst drug consumers in general
D2.4. Level of knowledge of product, effects and perceptions among con-
sumers of product
D2.5. General population
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D3. Prevalence and patterns of use
D3.1. Extent of use of product
D3.2. Frequency of use
D3.3. Route(s) of administration
D3.4. Other drugs used in combination with product
D3.5. Geographical distribution of use
D3.6. Trends in prevalence and patterns of use
D4. Characteristics and behaviour of users
D4.1. Age and gender of users
D4.2. Social groups where product available/used
D4.3. Risk behaviours associated with use
D4.4. Special concerns about vulnerable groups
D4.5. Trends in characteristics/behaviours of users
D5. Indicators of health consequences
D5.1. Hospital emergencies
D5.2. Deaths (direct and indirect)
D5.3. Traffic accidents
D5.4. Requests for treatment/counselling
D5.5. Other health indicators
D6. Context of use
D6.1. Risk factors linked to circumstances and rituals of consumption
D7. Implications for the non-using population
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The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of
11 decentralised agencies set up by the European Union to carry out specialised
technical or scientific work. 
The Centre’s main goal is to provide ‘objective, reliable and comparable information at
European level concerning drugs and drug addiction and their consequences’.
Through the statistical, documentary and technical information it gathers, analyses
and disseminates, the Centre provides its audience — whether policy-makers,
practitioners in the drugs field or European citizens — with an overall picture
of the drug phenomenon in Europe.
The Centre’s main tasks are:
l collecting and analysing existing data;
l improving data-comparison methods;
l disseminating information; and
l cooperating with European and international bodies 
and organisations and with non-EU countries.
The EMCDDA works exclusively in the field of information.
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for the risk assessment of
new synthetic drugs
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